Inhibitors of mTOR

Heinz Josef Klümpen, Jos H. Beijnen, Howard Gurney, Jan H M Schellens

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.

LanguageEnglish
Pages1262-1269
Number of pages8
JournalOncologist
Volume15
Issue number12
DOIs
Publication statusPublished - Dec 2010
Externally publishedYes

Fingerprint

Sirolimus
Pharmaceutical Preparations
Pharmacogenetics
Drug Interactions
Renal Cell Carcinoma
Drug Resistance
Therapeutics
Pharmacokinetics
Neoplasms

Cite this

Klümpen, H. J., Beijnen, J. H., Gurney, H., & Schellens, J. H. M. (2010). Inhibitors of mTOR. Oncologist, 15(12), 1262-1269. https://doi.org/10.1634/theoncologist.2010-0196
Klümpen, Heinz Josef ; Beijnen, Jos H. ; Gurney, Howard ; Schellens, Jan H M. / Inhibitors of mTOR. In: Oncologist. 2010 ; Vol. 15, No. 12. pp. 1262-1269.
@article{38c02727846b4b1abdef7557e04e2d97,
title = "Inhibitors of mTOR",
abstract = "Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.",
author = "Kl{\"u}mpen, {Heinz Josef} and Beijnen, {Jos H.} and Howard Gurney and Schellens, {Jan H M}",
year = "2010",
month = "12",
doi = "10.1634/theoncologist.2010-0196",
language = "English",
volume = "15",
pages = "1262--1269",
journal = "Oncologist",
issn = "1083-7159",
publisher = "AlphaMed Press",
number = "12",

}

Klümpen, HJ, Beijnen, JH, Gurney, H & Schellens, JHM 2010, 'Inhibitors of mTOR', Oncologist, vol. 15, no. 12, pp. 1262-1269. https://doi.org/10.1634/theoncologist.2010-0196

Inhibitors of mTOR. / Klümpen, Heinz Josef; Beijnen, Jos H.; Gurney, Howard; Schellens, Jan H M.

In: Oncologist, Vol. 15, No. 12, 12.2010, p. 1262-1269.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Inhibitors of mTOR

AU - Klümpen, Heinz Josef

AU - Beijnen, Jos H.

AU - Gurney, Howard

AU - Schellens, Jan H M

PY - 2010/12

Y1 - 2010/12

N2 - Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.

AB - Inhibitors of mammalian target of rapamycin (mTOR) have been approved for the treatment of renal cell carcinoma and appear to have a role in the treatment of other malignancies. The primary objective of this drug review is to provide pharmacokinetic and dynamic properties of the commonly used drugs everolimus and temsirolimus. Additionally, information on clinical use, mechanism of action, bioanalysis, drug-drug interactions, alterations with disease or age, pharmacogenetics, and drug resistance is given. This overview should assist the treating medical oncologist in adjusting treatment with mTOR inhibitors to individual patient circumstances.

UR - http://www.scopus.com/inward/record.url?scp=78650971226&partnerID=8YFLogxK

U2 - 10.1634/theoncologist.2010-0196

DO - 10.1634/theoncologist.2010-0196

M3 - Review article

VL - 15

SP - 1262

EP - 1269

JO - Oncologist

T2 - Oncologist

JF - Oncologist

SN - 1083-7159

IS - 12

ER -

Klümpen HJ, Beijnen JH, Gurney H, Schellens JHM. Inhibitors of mTOR. Oncologist. 2010 Dec;15(12):1262-1269. https://doi.org/10.1634/theoncologist.2010-0196